Literature DB >> 8395912

Myeloperoxidase: expression and modulation in a large panel of human leukemia-lymphoma cell lines.

Z B Hu1, W Ma, C C Uphoff, K Metge, S M Gignac, H G Drexler.   

Abstract

Myeloperoxidase (MPO) is found exclusively in the azurophilic granules (primary lysosomes) of normal myelomonocytic cells. Cytochemical staining for MPO activity is used clinically to distinguish myeloid from lymphoid leukemias. We studied the expression of MPO at the RNA and protein level in 140 continuous human leukemia-lymphoma cell lines using classical cytochemistry, immunofluorescent staining with a specific monoclonal antibody, Northern blot analysis, and a reverse transcription-polymerase chain reaction (RT-PCR) amplification assay. Seventy-eight lymphoid leukemia, myeloma, and lymphoma cell lines were negative; only 3 pre-B-acute lymphoblastic leukemia (ALL) cell lines were MPO-positive. Two of these MPO-positive pre-B-ALL cell lines showed a trace expression after RT-PCR and Southern blotting corresponding to 4% to 6% of the transcripts found in other positive myeloid cell lines. The third pre-B-ALL cell line was positive in Northern blots and cytochemical/immunofluorescent staining; however, only few cells were weakly positive in the latter assay. Although 15 of 59 cell lines assigned to the myeloid, monocytic, megakaryocytic, or erythroid lineages were MPO-positive in Northern blots, those 15 and 13 additional cell lines showed bands of mRNA after RT-PCR. MPO protein was detected in all 16 Northern-positive cell lines; on the other hand, there were 4 cell lines that were protein-positive, but Northern-negative. Differentiation induced by protein kinase C activators 12-O-tetradecanoylphorbol 13-acetate and Bryostatin 1 or by all-trans retinoic acid was associated with a decrease in MPO mRNA in all 7 initially positive cell lines studied, even leading to the complete absence of transcripts, but the enzymatic activity of the differentiated cells was only slightly less than that of unstimulated cells. MPO expression could not be induced in 10 initially negative cell lines. The half-life of MPO mRNA was found to be about 6 hours and was not shortened by prior exposure of the cells to the differentiation-inducing agents. These results confirm that MPO expression is mainly associated with myelomonocytic cells, but also underline the notion that MPO cannot be used as an absolutely lineage-specific marker for the distinction of leukemic cells. MPO can be used as an excellent parameter to characterize the various stages of normal and induced differentiation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8395912

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  5 in total

1.  Establishment and characterization of new B-cell precursor leukemia cell line NALM-35.

Authors:  Yoshinobu Matsuo; Hans G Drexler; Akira Harashima; Nobuharu Fujii; Fumihiko Ishimaru; Kunzo Orita
Journal:  Hum Cell       Date:  2002-12       Impact factor: 4.174

2.  Diagnosis of biphenotypic acute leukemia: a paradigmatic approach.

Authors:  Xianfeng Frank Zhao; Ivana Gojo; Teresa York; Yi Ning; Maria R Baer
Journal:  Int J Clin Exp Pathol       Date:  2009-10-10

3.  Myeloperoxidase Enhances Etoposide and Mitoxantrone-Mediated DNA Damage: A Target for Myeloprotection in Cancer Chemotherapy.

Authors:  Mandeep Atwal; Emma L Lishman; Caroline A Austin; Ian G Cowell
Journal:  Mol Pharmacol       Date:  2016-11-10       Impact factor: 4.436

4.  BET-Independent Murine Leukemia Virus Integration Is Retargeted In Vivo and Selects Distinct Genomic Elements for Lymphomagenesis.

Authors:  Ivan Nombela; Martine Michiels; Dominique Van Looveren; Lukas Marcelis; Sara El Ashkar; Siska Van Belle; Anne Bruggemans; Thomas Tousseyn; Jürg Schwaller; Frauke Christ; Rik Gijsbers; Jan De Rijck; Zeger Debyser
Journal:  Microbiol Spectr       Date:  2022-07-19

5.  Novel myeloperoxidase-derived HLA-A2-restricted peptides as therapeutic targets against myeloid leukemia.

Authors:  Sijie Lu; Eran Tallis; Xiaoling Ding; Dan Li; Kathryn Cox; M James You; Lisa St John; Gheath Alatrash; Qing Ma; Jeffrey J Molldrem
Journal:  Cytotherapy       Date:  2021-06-30       Impact factor: 6.196

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.